Skip to main content
Nobukatsu Sawamoto on Muck Rack

Nobukatsu Sawamoto

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Nobukatsu

Contact Nobukatsu, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson’s disease - Nature

|
By Nobukatsu Sawamoto, Daisuke Doi, Yasutaka Fushimi, Tomohisa Okada, Tetsuhiro Kikuchi, Asuka Morizane, Takayuki Anazawa, Takero Shindo, Yoshiki Arakawa, Ryosuke Takahashi
| Nature Verified
Abstract Parkinson’s disease is caused by the loss of dopamine neurons, causing motor symptoms. Initial cell therapies using fetal tissues showed promise but had complications and ethical concerns1,2,3,4,5. Pluripotent stem (PS) cells emerged as a promising alternative for developing safe and effective treatments6. In this phase I/II trial at Kyoto University Hospital, seven patients (ages 50–69) received bilateral transplantation of dopaminergic progenitors derived from induced PS (iPS) cells.
Open in Who Shared Issue with article?
See all 1 articles